Introduction {#cesec10}
============

Psychotic disorders are associated with substantial premature mortality,[@bib1], [@bib2] morbidity,[@bib3] and a large social and financial burden.[@bib4] Yet, research into their distribution and determinants has only in the past decade extended beyond North America[@bib5] and northern Europe[@bib6], [@bib7], [@bib8] to southern Europe,[@bib9], [@bib10], [@bib11], [@bib12] South America,[@bib13] Africa,[@bib14], [@bib15] and other low-income and middle-income countries (LMICs).[@bib15], [@bib16] These new data might provide new clues to the determinants of the heterogeneity in the incidence of psychotic disorders between and within different populations reported in previous studies,[@bib17], [@bib18] aiding both service planning and our understanding of cause; both are crucial for planning effective public mental health responses. The most recent comprehensive systematic review and meta-analysis[@bib17] was published in 2004 and was restricted to schizophrenia. Further meta-analyses have limitations in terms of single country coverage,[@bib18] search scope, yield and assessment of heterogeneity,[@bib19] specific population group coverage[@bib20], [@bib21] or coverage of a particular risk factor,[@bib22], [@bib23], [@bib24], [@bib25], [@bib26] or were also restricted to schizophrenia.[@bib27]

Together, these reviews showed that estimates of the incidence of psychotic disorders vary across replicable demographic, geographical, and social characteristics. Men and young people appear to have an excess risk,[@bib27], [@bib28] as do migrants and their descendants.[@bib20], [@bib29], [@bib30] Settings at higher latitude and more urban settings also yield higher incidences.[@bib26], [@bib31] Socioeconomic deprivation, inequality, and instability are also associated with increased incidence.[@bib14], [@bib32], [@bib33], [@bib34] Earlier meta-analyses[@bib17], [@bib18], [@bib35] found no evidence of variation in incidence by study quality or other methodological features. Research suggests[@bib36], [@bib37] that higher incidences are derived from population registers (which cover all health-care contacts within an entire health system) than from first-contact studies (which rely on individuals making contact with appropriate services). These comparisons notwithstanding, methodological heterogeneity as an explanation for variation in incidences has not been investigated widely.

We sought to synthesise the accumulating research on the incidence of adult-onset psychotic disorders (including affective psychotic disorders) and investigate whether sociodemographic factors or methodological heterogeneity accounted for any observed variation. Consistent with available evidence, we hypothesised that incidences would be higher in men, younger people, and those from ethnic minority groups, and in register-based studies.

Research in context**Evidence before this study**We searched PubMed and Web of Science ([appendix p 4](#sec1){ref-type="sec"}) for international systematic reviews and meta-analyses of the incidence of non-organic psychotic disorders in the general population, published since the last major review of the evidence (published in 2004). Our search yielded 156 results, of which 14 were meta-analyses. However, these commonly examined a single risk factor for psychotic disorders, such as migrant status, or synthesised evidence of incidence in a particular segment of the population, such as the elderly. Only one meta-analysis met all inclusion criteria and summarised incidence in the general population, but this study provided no assessment of heterogeneity.**Added value of this study**To the best of our knowledge, this study is the first comprehensive systematic review and meta-analysis of the incidence of non-organic adult-onset psychotic disorders done in 16 years and provides an update on the epidemiological landscape. For the first time, we also formally assessed if incidence of psychotic disorders varies by study type. Incidence varied substantially between settings: a 10 times variation in incidence was observed across diagnostic categories. We also found that studies with routine registers reported higher incidences of disorder than studies with a service-based design.**Implications of all the available evidence**Variance in the incidence of psychotic disorders worldwide arises from both replicable social, demographic, and environmental determinants, and from methodological heterogeneity. Although most studies continue to be done in a handful of countries, future studies across more diverse settings will benefit from standardised methods to facilitate comparable estimates of incidence across the globe.

Methods {#cesec20}
=======

Search strategy and selection criteria {#cesec30}
--------------------------------------

This systematic review and meta-analysis followed PRISMA guidelines[@bib38] ([appendix pp 2--3](#sec1){ref-type="sec"}), including preregistering our protocol with PROSPERO (CRD42018086800) before extraction of data. Our method is based on a previous systematic review.[@bib18]

We systematically searched PubMed, PsycINFO, Web of Science, and Embase, adapting a previously used search strategy[@bib18] based on Cochrane Systematic Reviewing guidelines.[@bib39] This strategy used terms covering psychotic disorders and incidence and was adapted for each database ([appendix p 4](#sec1){ref-type="sec"}). We searched bibliographies of included citations and directly contacted authors to request data, where appropriate. We restricted our review to studies published between Jan 1, 2002, and Dec 31, 2017. We had no restriction on language of publication, study design, or publication status, although grey literature was only identified via published conference proceedings, author correspondence, and bibliographical searches.

Citations were considered eligible if they contained incidence data or data from which incidence could be derived (numerator and denominator); included patients (aged 18--64 years) diagnosed with a first episode of any psychotic disorder; were published between Jan 1, 2002, and Dec 31, 2017, and were published in the scientific or grey literature, online, or in print.

Two authors (HEJ, CT) carried out searches and screened the titles found to assess whether they met eligibility criteria, with definite or possible titles forwarded to duplicate independent abstract review and, if appropriate, full text review. Uncertainties about inclusion were resolved in agreement with two senior authors with experience in epidemiological research and systematic reviewing (JBK, PBJ). The [study protocol](https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=86800){#interrefs10} is available online.

Data analysis {#cesec40}
-------------

Two authors (HEJ, CT) extracted data. Study-level data about study characteristics, rate-level data about incidences, and meta-level data on time period, study quality, study design, and diagnostic criteria (see below) were included.

The primary outcome was incidence per 100 000 person-years of all psychotic disorders (International Classification of Disease tenth edition \[ICD-10\] = equivalent, F20--33), non-affective disorders (F20--29), schizophrenia (F20), affective disorders (F30--33), bipolar disorder with psychosis (F30--31), psychotic depression (F32--33), or substance-induced psychosis (F1X.5). Included studies used a range of diagnostic classifications, including ICD-8, ICD-9, and ICD--10, and the Diagnostic and Statistical Manual of Mental disorders (DSM) versions 3-R and 4, and we assumed sufficient commonalities to pool citations ([appendix p 5](#sec1){ref-type="sec"}).

Where possible, we extracted summary-level incidence data on the exposures age, sex, ethnicity, and migrant status. Meta-level data on study design, study quality, and time period were recorded. Study design was divided into first-contact studies (which count the number of people attending the relevant service, and include first presentation, first diagnosis, first GP record, first admission, and first treatment), cohort studies, case-register studies (with a dedicated national patient register), and studies with a general population register covering an entire health system. Time period was defined as the median year of the case ascertainment period. Where incidences were not directly reported, we derived them from ancillary information wherever possible. Where citations reported overlapping data from the same study or population, we used set criteria to establish inclusion ([appendix p 4](#sec1){ref-type="sec"}).

The full [spreadsheet](https://doi.org/10.17605/OSF.IO/2T7X4){#interrefs20} containing all study-level, rate-level, and meta-level data is available online.

Two independent raters (HEJ, JBK or CT) assessed study quality according to seven previously published criteria:[@bib18] designation of a defined catchment area, accurate reporting and reliable source of denominator data, population-based case finding, standardised research diagnosis used, masking (of the clinician) to demographic variables, inclusion criteria stated, and inclusion of a leakage study ([appendix p 4](#sec1){ref-type="sec"}).

We first did a narrative synthesis of the yield. Based on previous meta-analyses,[@bib17], [@bib18] we anticipated high levels of heterogeneity and therefore specified use of random-effects meta-analysis and meta-regression a priori to quantify this heterogeneity. When five or more incidences could be pooled, we did random-effects meta-analyses using the DerSimonian and Laird method,[@bib40] grouping citations by study design. We transformed incidence rates to their natural logarithm and entered into meta-analyses with corresponding standard errors (SE)s. If no SE could be derived, we retained studies for narrative synthesis only. For assessments of differences in incidence by sex and ethnicity, we estimated incidence rate ratios (IRRs), transformed them to their natural logarithm, and entered them into meta-analyses with their corresponding SEs.

We assessed statistical heterogeneity using the *Q* test and quantified using the *I*^2^ statistic, which identifies the proportion of the observed variance that reflects real differences in effect size. We examined evidence of small study effects (including publication bias) by visual inspection of funnel plots and formal testing using Egger\'s test for which at least 10 estimates were available.[@bib41] We did random-effects meta-regression to explore whether heterogeneity was associated with study quality, study design, or time period.

We did meta-analyses in Stata (version 13)[@bib42] using the metan and admetan commands. We did meta-regressions using the metareg package, and we did funnel plots and Egger\'s tests using the metafunnel and metabias packages.

We chose to display pooled estimates to prevent ad-hoc summaries of data but considering the high expected heterogeneity, the emphasis in interpretation of results is on the variation in incidences.

Role of the funding source {#cesec50}
--------------------------

There was no funding source for this study.

Results {#cesec60}
=======

We retrieved 56 721 records of which 177 met inclusion criteria ([figure 1](#fig1){ref-type="fig"}; [table](#tbl1){ref-type="table"}); 93 (53%) of 177 had sufficient data available for meta-analysis and meta-regression. Most studies (140 \[79%\] of 177) were done in Europe, with 14 (8%) done in North America. Few studies were done in Asia (11 \[6%\]), the Middle East (seven \[4%\]), Australia, Latin or South America (four \[2%\] each), or Africa (two \[1%\]). Two citations covered more than one continent.[@bib15], [@bib55] Citations examining psychosis in young people (26 \[15%\]), comorbid groups (12 \[7%\]), the army (seven \[4%\]), a prison population (one \[\<1%\]), and post-partum psychosis (five \[3%\]) are synthesised in the [appendix (pp 8--12)](#sec1){ref-type="sec"} because they are not representative of the general population. The most frequently studied diagnostic outcome was schizophrenia (86 \[49%\]), followed by all non-affective disorders (66 \[37%\]) and all psychotic disorders (59 \[33%\]). Any affective psychotic disorder as an outcome was less frequently studied (32 \[18%\]), although we identified 40 (22%) citations of bipolar disorder with psychosis and 15 (8%) citations of psychotic depression. Six (3%) citations examined substance-induced psychosis.Figure 1PRISMA flowchart\*Citations derived from Kirkbride and colleagues,[@bib18] which cover England only from 2002--09.TableStudy characteristics of included citations**CountryPeriodTypeDiagnostic confirmationDiagnostic classificationDiagnostic outcomesNumber of cases**Tsuchiya et al 2002^61^[\*](#tbl1fn1){ref-type="table-fn"}Denmark1980--97First admission..ICD-8, ICD-10SchzUnknownHanoeman et al 2002^62^[\*](#tbl1fn1){ref-type="table-fn"}Surinam1992--93First admissionMedical recordsDSM-3-RSchz, schzp73Selten et al 2002^63^[†](#tbl1fn2){ref-type="table-fn"}Netherlands1970--92Case registerNoneICD-8, ICD-9SchzUnknownBaldwin et al 2002^64^[‡](#tbl1fn3){ref-type="table-fn"}Ireland1995--2000First contactSCID or medical recordsDSM-4FEP69Scully et al 2002^65^[\*](#tbl1fn1){ref-type="table-fn"}Ireland1995--2000First contactSCID or medical records..FEP69Boydell et al 2003^66^[\*](#tbl1fn1){ref-type="table-fn"}England1965--97Case registerCase notes plus OPCRITCombinationSchz623; 385Smith et al 2003^67^[‡](#tbl1fn3){ref-type="table-fn"}Canada1907--13First admissionClinical recordsDSM-4Schz, schzp, bpd831Singh et al 2003^68^England2000First contactInterview, questionnaire, case notes..FEP295Selten et al 2003^69^Netherlands1990--96Case registerDischarge summaryICD-9Bpd, pd14 749Cantor-Graae et al 2003^70^[‡](#tbl1fn3){ref-type="table-fn"}Denmark1970--98Population registerNoneICD-8, ICD-10Schz10 244Baldwin et al 2003^71^[‡](#tbl1fn3){ref-type="table-fn"}Ireland1995--2002First contactSCID or clinical recordsDSM-4FEP, non-aff, schiz, aff, bp, pd, other146Proctor et al 2004^72^England1998--2001Case registerChart diagnosisICD-10FEP, non-aff, schz, aff, bp, pd, sip, other227Sipos et al 2004^73^Sweden1989--2001First admissionNoneICD-9, ICD-10Non-aff, schz1950Chien et al 2004^74^[‡](#tbl1fn3){ref-type="table-fn"}Taiwan1997--2001First contactNoneICD-9Schz419Boydell et al 2004^75^[\*](#tbl1fn1){ref-type="table-fn"}England1988--97CombinationCase records using OCCPIRDCSchz222Veen et al 2004^76^Netherlands1997--99First contactDiagnostic meetingDSM-4FEP, non-aff, aff, oth181Singh et al 2004^77^England1992--94First contactInterview, SCAN or SANS and OCCPI or OPCRITICD-10FEP, non-aff, schz, aff, sip, oth168Sailas et al 2005^78^[§](#tbl1fn4){ref-type="table-fn"}Finland1984--94CohortNoneOtherFEP71Harris et al 2005^79^[\*](#tbl1fn1){ref-type="table-fn"}[†](#tbl1fn2){ref-type="table-fn"}Australia..First presentationConsensusDSM-4, ICD-10FEP, schz, aff94Sundquist et al 2005^80^[‡](#tbl1fn3){ref-type="table-fn"}Sweden1997--99Population registerNoneICD-9, ICD-10FEP, pd6163Nager et al 2005^81^[¶](#tbl1fn5){ref-type="table-fn"}Sweden1986--97CohortNoneICD-9, ICD-10FEP339Laursen et al 2005^82^[‡](#tbl1fn3){ref-type="table-fn"}Denmark1952--87Population registerNoneICD-8, ICD-10Schz, schza, bp18 147Selten et al 2005^83^Surinam2002--03First contactCASH interview, panel discussionDSM-4FEP64Nixon et al 2005^84^England1881--1994CombinationCase notesRDCSchz41Qin et al 2005^85^[‖](#tbl1fn6){ref-type="table-fn"}Denmark1950--87Population registerNoneICD-8, ICD-10Non-aff, schz795Allardyce et al 2005^86^Scotland1989--93First admissionCase recordICD-9FEP5838Cantor-Graae et al 2005^87^Sweden1999--2001First contactClinical, case records, additional dataDSM-4FEP, non-aff150Baldwin et al 2005[@bib43]Ireland1995--2003First contactSCID or clinical diagnosisDSM-4FEP, non-aff, schz, aff, bpd, pd, oth194Kennedy et al 2005a^88^England1965--99CombinationCase notes plus OPCRITDSM-4Bpd246Kennedy et al 2005b^89^[\*](#tbl1fn1){ref-type="table-fn"}England1965--99CombinationCase notes plus OPCRITDSM-4, ICD-10Bpd246; 235Lloyd et al 2005^90^[‡](#tbl1fn3){ref-type="table-fn"}England1997--99First contactInterview (SCAN, SANS, modified PPHS), consensus diagnosisICD-10Bpd75Leão et al 2006[@bib8][†](#tbl1fn2){ref-type="table-fn"}Sweden1992--99Population registerNoneICD-9, ICD-10Non-affUnknownBray et al 2006^91^[†](#tbl1fn2){ref-type="table-fn"}Canada1975--85First contactNoneICD-10Schz1962Payne et al 2006^92^Canada1993--95First admissionClinical records..Non-aff146Drukker et al 2006^93^Netherlands1993--2002Case registerNoneDSM-4Schz98Turner et al 2006^94^[\*\*](#tbl1fn7){ref-type="table-fn"}England1999--2002First admissionCase notes, ratified by psychiatristICD-10Non-aff, schz62Mahmmood et al 2006^95^England2005--05First contactUnknown..FEP303Westman et al 2006^96^[‡](#tbl1fn3){ref-type="table-fn"}Sweden1997--98Population registerNoneICD-9, ICD-10FEP10 800Munk-Olsen et al 2006^97^[¶](#tbl1fn5){ref-type="table-fn"}Denmark1955--90Population registerNoneICD-8, ICD-10Non-aff, schz166Smith et al 2006[@bib44]Canada1902--13First admissionClinical recordsDSM-4Schz, schza, schp, oth807Amminger et al 2006^98^[†](#tbl1fn2){ref-type="table-fn"}Australia1997--2000First treatmentYouth assessment team, random sample SCID or RPMIPDSM-4FEP1019Veling et al 2006[@bib7]Netherlands1997--2005First contactDiagnostic meetingDSM-4Non-aff181Morgan et al 2006^99^[‡](#tbl1fn3){ref-type="table-fn"}England1997--99First contactInterview (SCAN), case notes, consensus meetingICD-10FEP, schz592Fearon et al 2006^100^[\*](#tbl1fn1){ref-type="table-fn"}England1997--99First contactInterview (PSE SCAN), case notes (IGC SCAN)ICD-10FEP, schz, bpd, pd, oth568Gould et al 2006^101^England1997--99First presentationWHO screening for psychosis plus OPCRITICD-10FEP111Kirkbride et al 2006[@bib6]England1997--99First contactSCAN, consensus panelDSM-4FEP, non-aff, schz, aff, sip568Zipursky et al 2006^102^England1997--99First contactSCAN, consensus panelDSM-4FEP, schzUnknownLi et al 2007^103^Sweden1984--2004Population registerNoneICD-9, ICD-10FEP40 228Schimmelmann et al 2007^104^[\*](#tbl1fn1){ref-type="table-fn"}Australia1998--2000First admissionSCID and clinical diagnosis comparisonDSM-4FEP636Laursen et al 2007^105^Denmark1995--87Population registerNoneICD9, ICD-10Schz, bpd17 787Ajdacic-Gross et al 2007^106^[†](#tbl1fn2){ref-type="table-fn"}Switzerland1977--2005Case registerNoneICD-8, ICD-9FEP, schz7230Andersen et al 2007^107^Norway1887--2005First admissionCase recordsICD-10Schz, aff64Harlow et al 2007^108^Sweden1987--2001CohortNoneICD-8, ICD-9Non-aff, schz, schza, bpd2134Juvonen et al 2007^109^[‖](#tbl1fn6){ref-type="table-fn"}Finland1950--59Population registerCase notes (2 experts)DSM-4Schz807Cantor-Graae et al 2007a^110^[‡](#tbl1fn3){ref-type="table-fn"}Denmark1986--2006Population registerNoneICD-8, ICD-10Schz4609Cantor-Graae et al 2007b^111^[‡](#tbl1fn3){ref-type="table-fn"}Denmark1970--2001Population registerNoneICD-8, ICD-10Schz10 779Leão et al 2007^112^[\*](#tbl1fn1){ref-type="table-fn"}[†](#tbl1fn2){ref-type="table-fn"}Sweden1995--98Population registerNoneICD-9, ICD-10Non-aff, affUnknownKikbride et al 2007a^113^England1997--99First contactSCAN, consensus panelICD-10FEP, non-aff, aff295Menezes et al 2007[@bib13]Brazil2002--2004First contactSCID-I or case notesDSM-4FEP, non-aff, aff367Kirkbride et al 2007b^114^[‡](#tbl1fn3){ref-type="table-fn"}England1997--99First contactSCAN, consensus panelICD-10Non-aff, schz, oth218Stain et al 2008^115^[†](#tbl1fn2){ref-type="table-fn"}Australia2001--2005First contactCase notesOtherOth308Boonstra et al 2008^116^Netherlands2002First contactClinical diagnosisDSM-4Non-aff75Crebbin et al 2008^117^[\*](#tbl1fn1){ref-type="table-fn"}England1998--2005Case registerChart diagnosisICD-10FEP, schz, pd540Farquhar et al 2008[@bib45]Wales1875--2005First admissionCase recordsICD-10Schz, schza, aff, bpd, pd, oth579Pelayo-Teran et al 2008[@bib10]Spain2001--05First contactSCID-IDSM-4Non-aff174Castagnini et al 2008^118^[\*](#tbl1fn1){ref-type="table-fn"}Denmark1996Case registerNoneICD-8Schz, bpd, oth11 126Burns et al 2008[@bib14]South Africa2005First presentationCase recordsDSM-4FEP160Weiser et al 2008^119^Israel..Population registerNoneICD-9, ICD-10Schz1686Veling et al 2008^120^Netherlands1997--2005First contactDiagnostic meetingDSM-4FEP, non-aff, bpd, pd, oth466Kirkbride et al 2008a^121^[‡](#tbl1fn3){ref-type="table-fn"}England1997--99First contactSCAN, consensus panelICD-10Schz148Kirkbride et al 2008b^122^England1996--2000First contactSCAN, consensus panelDSM-4FEP, schz, non-aff, oth484Coid et al 200^123^England1996--2000First contactSCAN, consensus panelDSM-4FEP, non-aff, schz, aff, oth484Grant et al 200^124^[††](#tbl1fn8){ref-type="table-fn"}USA2004--05CohortNot statedDSM-4Bpd263Crebbin et al 2009^125^[\*](#tbl1fn1){ref-type="table-fn"}England1998--2005Case registerChart diagnosisICD-10Schz, sip430Bih et al 2009^126^[\*](#tbl1fn1){ref-type="table-fn"}[††](#tbl1fn8){ref-type="table-fn"}Taiwan1996--2003CohortNoneICD-9Bpd532Corcoran et al 2009^127^[†](#tbl1fn2){ref-type="table-fn"}Israel1964--97CohortNoneICD-10Non-aff637Osby et al 2009^128^[\*](#tbl1fn1){ref-type="table-fn"}Sweden1997--2005Case registerNoneICD-10Bpd4117Valdimarsdottir et al 2009^129^[¶](#tbl1fn5){ref-type="table-fn"}Sweden1983--2000CohortNoneICD-8, ICD-9FEP4557Harlap et al 2009^130^Israel1964--76CohortNoneICD-10Schz637Reay et al 2009^131^England1998--2005First contactChart diagnosisICD-10FEP, non-aff, schz, aff, bpd, pd540Norredam et al 2009^132^Denmark1994--2003CohortNoneICD-10Non-aff1127Bogren et al 2009^133^Sweden1947--97First contactKey informants, case filesDSM-4Non-aff, schz, schza, aff, bpd61Kirkbride et al 2009^134^[‡](#tbl1fn3){ref-type="table-fn"}England1978--99CombinationSCAN, consensus agreementICD-9, ICD-10FEP, non-aff, schz, aff, bpd, pd, sip, oth347Coid et al 2009^123^\...\...\...\.....Cheng et al 2010^135^[†](#tbl1fn2){ref-type="table-fn"}England2002--2007First contactUnsureICD-10FEP285Bogren et al 2010[@bib46]Sweden1947--97First presentationKey informants, case filesDSM-4Non-aff, aff, bpd108Zammit et al 2010^136^[‡](#tbl1fn3){ref-type="table-fn"}Sweden1972, 1977First admissionNoneICD-8, ICD-9Non-aff, schz881Tseng et al 2010^137^Taiwan1996--2001First hospitalisationNoneICD-9SchzUnknownZandi et al 2010^138^Netherlands2002--04First contactCASH or CASH-CS, medical files, consensus diagnosisDSM-4FEP, schz77Norredam et al 2010^139^[‡](#tbl1fn3){ref-type="table-fn"}Denmark1994--2003CohortNoneICD-10Non-aff791Goodman et al 2011[@bib47][\*\*](#tbl1fn7){ref-type="table-fn"}USA..First contactNot statedICD-9FEP8Cowan et al 2011^140^[\*\*](#tbl1fn7){ref-type="table-fn"}USA2000--09First hospitalisationNoneICD-9Non-aff2722Harris et al 2011^141^[\*](#tbl1fn1){ref-type="table-fn"}Wales1875--2005First admissionPanel assessment of case notesICD-10Pd800Jorgensen et al 2011^142^Sweden2005Case registerRandom sample checked by psychiatristICD-10Non-aff, schz416Cheng et al 2011^143^[†](#tbl1fn2){ref-type="table-fn"}England2002--07First contactMultidisciplinary diagnostic meetingICD-10FEP285Kleinhaus et al 2011^144^[†](#tbl1fn2){ref-type="table-fn"}Israel1964--76CohortNoneICD-10Non-aff860Benros et al 2011^145^[‖](#tbl1fn6){ref-type="table-fn"}Denmark1945--96Population registerNoneICD-8, ICD-10Non-aff39 076Salokangas et al 2011^146^Finland..Case registerNoneICD-8, DSM-3-R, ICD-10Schz30 032Schofield et al 2011^147^England1996--2006First GP recordPatient recordsREAD codesFEP508Veling et al 2011^148^Netherlands1997--2005First contactDiagnostic meetingDSM-4FEP618Healy et al 2012^149^[\*](#tbl1fn1){ref-type="table-fn"}Wales1875--2005First admissionCase records, clinical diagnosisICD-10Schz, oth3523Callaghan et al 2012^150^[\*](#tbl1fn1){ref-type="table-fn"}USA1990--2000First hospitalisationNot statedICD-9Schz1499Anderson et al 2012^151^[†](#tbl1fn2){ref-type="table-fn"}Canada2000--06First contactNone..Non-aff546Manrique-Garcia et al 2012^152^[\*\*](#tbl1fn7){ref-type="table-fn"}Sweden1969--70First admissionNoneICD-8, ICD-9Non-aff, schz674Turola et al 2012^153^Italy1979--2008First diagnosisCase notesDSM-4, ICD-10Schz1759Werbeloff et al 2012^154^Israel1979--92Case registerNoneICD-9Schz2335Nosarti et al 2012^155^[†](#tbl1fn2){ref-type="table-fn"}Sweden1973--85First admissionNoneICD-8 and ICD-9Non-aff, bpd886Gigantesco et al 2012^156^Italy2008First contactSCID-I, BPRS, GAF in duplicateDSM-4FEP, bpd247Tarricone et al 2012[@bib11]Italy2002--09First contactSCAN, consensus diagnosisICD-10FEP, Non-aff, schz, aff163Kirkbride et al 2012^157^[†](#tbl1fn2){ref-type="table-fn"}England2009--11First presentationClinical diagnosesICD-10FEP..Hung et al 2013^158^[‖](#tbl1fn6){ref-type="table-fn"}[††](#tbl1fn8){ref-type="table-fn"}Taiwan2000--05CohortNoneICD-9Bpd9711Peritogiannis et al 2013^159^Greece2008--09First contactNoneICD-10FEP132Sutterland et al 2013^160^Netherlands1996--2006First GP recordMedical recordsICPCNon-aff, schz293Cantor-Graae et al 2013^161^[†](#tbl1fn2){ref-type="table-fn"}[‡](#tbl1fn3){ref-type="table-fn"}Denmark1995--2010Population registerNoneICD-8, ICD-10Non-aff, schz, schza, bpd13 729Kroon et al 2013^162^Netherlands1996--2007First GP recordMedical recordsICPCBpd649Castagnini et al 2013^163^[‡](#tbl1fn3){ref-type="table-fn"}Denmark1995--2008First diagnosisNoneICD-10Oth11 126Hardoon et al 2013^164^England2000--10First record or diagnosisGP recordsREADSchz, bpd, oth10 520Weibell et al 2013^165^Norway2007--11First presentationSCIDDSM-4Non-aff, sip321Cocchi et al 2014^166^Italy2007--09First contactERIaos-CL, sociodemographic form, HoNOS, BPRS, WHO-DAS IIIICD-10Non-aff43Tortelli et al 2014^167^France2005--09First admissionCase notesICD-10FEP258Hogerzeil et al 2014[@bib37]Netherlands2000--05First contact and case registerDiagnostic meeting and clinical regularly audited)DSM-4Schz254; 843Pedersen et al 2014^168^[\*](#tbl1fn1){ref-type="table-fn"}Denmark1995--2006Case registerNoneICD-10OthUnknownSørensen et al 2014^169^[\*](#tbl1fn1){ref-type="table-fn"}Denmark1993--95Population registerNoneICD-8, ICD-10Schz17 389Munk-Olsen et al 2014^170^[¶](#tbl1fn5){ref-type="table-fn"}Denmark1960--95First treatmentNoneICD-8, ICD-9OthUnknownSzoke et al 2014^171^France2010--12First contactIdentical procedures, regular meetingsDSM-4FEP, non-aff, aff133Bhavsar et al 2014^172^[†](#tbl1fn2){ref-type="table-fn"}England2000--07First contactCase notesRDCSchz405Omer et al 2014^173^[‡](#tbl1fn3){ref-type="table-fn"}Ireland1995--2000First contactSCID or clinical recordsDSM-4FEP336Lasalvia et al 2014[@bib9]Italy2005--07First contactInterview, consensus diagnosisICD-10FEP, non-aff, schz, aff, bpd, pd558Veling et al 2014^174^Netherlands1997--2005First contactDiagnostic meetingDSM-4FEP, schz, aff, bpd, pd, oth618Kirkbride et al 2014[@bib34][‡](#tbl1fn3){ref-type="table-fn"}England1996--2000First contactSCAN, consensus diagnosisDSM-4Non-aff, aff484Anderson et al 2015[@bib5][†](#tbl1fn2){ref-type="table-fn"}Canada1999--2008Population registerMedical records or billing claimsNon-affUnknownPaksarian et al 2015a^175^[†](#tbl1fn2){ref-type="table-fn"}Denmark1986--2010Population registerNoneICD-8, ICD-10Non-aff, schz, bpd15 811Sørensen et al 2015^176^Denmark1955--67Population registerNoneICD-8, ICD-10Non, aff, schz, aff15 074; 7562Paksarian et al 2015b^177^Denmark1986--2011Population registerNoneICD-8, ICD-10Non-aff, schz, bpd14 285Soderlund et al 2015^178^[†](#tbl1fn2){ref-type="table-fn"}Sweden1955--67Population registerNoneICD-10Non-aff, schz, aff2322Medici et al 2015^179^[††](#tbl1fn8){ref-type="table-fn"}Denmark1995--2012Case registerNoneICD-10Bpd15 334Carlborg et al 2015^180^[††](#tbl1fn8){ref-type="table-fn"}Sweden1991--2010Case registerNoneICD-10Bpd10 273Tsai et al 2016^181^[‖](#tbl1fn6){ref-type="table-fn"}[††](#tbl1fn8){ref-type="table-fn"}Taiwan2000--07CohortNoneICD-9Bpd202Chen et al 2015^182^[‖](#tbl1fn6){ref-type="table-fn"}[††](#tbl1fn8){ref-type="table-fn"}Taiwan2000--06CohortNoneICD-9-CMBpd, pd118Latvala et al 2016^183^[\*\*](#tbl1fn7){ref-type="table-fn"}Sweden1969--2010Case registerNoneICD-8/9/10Schz, bpd14 840Jensen et al 2016^184^[\*](#tbl1fn1){ref-type="table-fn"}[††](#tbl1fn8){ref-type="table-fn"}Denmark1995--2010Case registerNoneICD-10Bpd12 034Kuhl et al 2016^185^[\*](#tbl1fn1){ref-type="table-fn"}Denmark2000--12Population registerNoneICD-10Non-aff, schz23 479Filatova et al 2016^186^[†](#tbl1fn2){ref-type="table-fn"}Finland1966--2013CohortNoneICD-8, ICD-10Non-aff, schz, bpd, oth295Chiang et al 2016[@bib48]Taiwan1998--2007First admissionNoneICD-9-CMFEP69 690Nielsen et al 2016^187^[‡](#tbl1fn3){ref-type="table-fn"}Denmark1997--2002Population registerNoneICD-8, ICD-10Schz6927Kendler et al 2016[@bib49]Sweden1972--90Population registerNoneICD-9, ICD-10Non-aff, schz, bpd22 589Levine et al 2016a^188^[\*](#tbl1fn1){ref-type="table-fn"}Israel1950--2004CohortNoneICD-10Schz2278Levine et al 2016b^189^[\*](#tbl1fn1){ref-type="table-fn"}Israel1950--2014CohortNoneICD-10Schz665Vassos et al 2016[@bib50][‡](#tbl1fn3){ref-type="table-fn"}Denmark1995--2006Population registerNoneICD-10FEP, non-aff, bpd32 983Sørensen et al 2016^190^[\*](#tbl1fn1){ref-type="table-fn"}Denmark1930--76CohortNoneICD-8, ICD-10Schz4936Hollander et al 2016^191^[†](#tbl1fn2){ref-type="table-fn"}Sweden1998--2011Population registerNoneICD-10Non-aff3704O\'Donoghue et al 2016^192^Ireland2006--11First presentationSCIDDSM-4FEP292Morgan et al 2016[@bib15]India, Nigeria, Trinidad..First contactSSP, consensus diagnosisICD-10FEP147Tarricone et al 2016^193^Italy2002--10First contactSCANICD-10FEP187Szoke et al 2016^194^France2010--14First contactUnclear---senior review if uncertainDSM-4Non-aff, aff212Mulé et al 2016[@bib12]Italy2008--11First contactSCANICD-10FEP, schz, aff, oth204Ramsey et al 2017[@bib51][\*\*](#tbl1fn7){ref-type="table-fn"}USA2001--14CohortNoneICD-9Schz, bpd24 714Okkels et al 2017^195^[‖](#tbl1fn6){ref-type="table-fn"}Denmark1985--2001Population registerNoneICD-8, ICD-10Non-aff, schz, bpd9329Vikstrom et al 2017^196^[¶](#tbl1fn5){ref-type="table-fn"}Sweden1988--2012CohortNoneICD-8, ICD-10Non-aff, bpd91Wang et al 2017^197^[‖](#tbl1fn6){ref-type="table-fn"}Taiwan1997--2007CohortNoneICD-9Schz238Lin et al 2017^198^[‖](#tbl1fn6){ref-type="table-fn"}[††](#tbl1fn8){ref-type="table-fn"}Taiwan2001--06CohortNoneICD-9 CMBpd183Marrie et al 2017a^199^[‖](#tbl1fn6){ref-type="table-fn"}Canada1989--2012Case registerNoneICD-9 CMSchz, bpdUnknownMarrie et al 2017b^200^[‖](#tbl1fn6){ref-type="table-fn"}Canada1984--2013Case registerNoneICD-9 CMSchz, bpdUnknownHogerzeil et al 2017^201^Netherlands2000--05First contact or case registerStructured interview or clinical, then consensusDSM-4Schz254; 843Hoeffding et al 2017^202^Denmark1995--2013Population registerNoneICD-8, ICD-10Non-aff31 647Kim et al 2017[@bib52]South Korea2002--13CohortNoneICD-10Non-aff9387Markkula et al 2017[@bib53]Finland2011--14Population registerNoneICD-10Non-aff, bpd2905Nielsen et al 2017^203^[‖](#tbl1fn6){ref-type="table-fn"}Denmark1955--99Population registerNoneICD-8, ICD-10Schz21 305Schofield et al 2017^204^Denmark1965--97Population registerNoneICD-8, ICD-10Non-aff26 891Simon et al 2017[@bib54]USA2007--13First contactNone, subset case recordsICD-9FEP37 843Kirkbride et al 2017a^205^[†](#tbl1fn2){ref-type="table-fn"}England2009--13First contactOPCRITICD-10FEP, non-aff, schz, aff, bpd, pd, sip687Kirkbride et al 2017b^206^[†](#tbl1fn2){ref-type="table-fn"}England2009--13First contactOPCRITICD-10FEP, non-aff, schz, aff687Schofield et al 2018^207^[‡](#tbl1fn3){ref-type="table-fn"}Denmark1965--2013Population registerNoneICD-8, ICD-10Non-affUnknownNyberg et al 2018^208^[\*\*](#tbl1fn7){ref-type="table-fn"}[‡‡](#tbl1fn9){ref-type="table-fn"}Sweden1968--2005CohortNoneICD-8, ICD-9, ICD-10Non-aff4641Barghadouch et al 2018^209^[†](#tbl1fn2){ref-type="table-fn"}[‡‡](#tbl1fn9){ref-type="table-fn"}Denmark1993--2000CohortNoneICD-10Non-aff392Richardson et al 2018^210^[†](#tbl1fn2){ref-type="table-fn"}[‡‡](#tbl1fn9){ref-type="table-fn"}England2009--13First contactOPCRITICD-10FEP, non-aff, schz, aff0687Jongsma et al 2018[@bib55]England, Netherlands, France, Spain, Italy, Brazil2005--15First contactSCAN, CASH, DIGS, SID, or case notes---OPCRITICD-10FEP, non-aff, aff2774[^1][^2][^3][^4][^5][^6][^7][^8][^9][^10]

The largest study in this Article[@bib48] included 69 690 cases, and the smallest study[@bib47] identified eight cases. The middle year of recruitment varied from 1908[@bib44] to 2012,[@bib53] with most citations (105 \[59%\]) recruiting between approximately 1995 and 2006. Most studies reported a clearly defined catchment area (174 \[98%\]), clearly listed their inclusion criteria (166 \[94%\]), used accurate denominator data (157 \[89%\]), and employed population-based case-finding (135 \[76%\]). Few studies done used a standardised research diagnosis (50 \[28%\]), did a leakage study (28·5 \[16%\]), or used blinding to demographic variables (18 \[10%\]; [appendix pp 6--8](#sec1){ref-type="sec"}). 92 (52%) citations reflected first contact designs and 76 (43%) used a cohort, case, or population register. The remaining nine (5%) studies used a combination. 40 (23%) citations used a version of the DSM for diagnoses and 118 (67%) used a version of ICD. The remaining 19 (11%) used a combination, used a different diagnostic system, such as the Research Diagnostic Criteria, or it was not reported (three \[2%\]; [table](#tbl1){ref-type="table"}). To confirm clinical diagnoses, 21 (12%) citations used a structured interview instrument only, 19 (11%) reviewed medical records, 14 (8%) used a structured interview followed by consensus diagnosis, 13 (7%) used only an interview without specifying whether an instrument was used, ten (6%) used only a consensus or panel discussion, and five (2%) used a chart or clinical diagnoses. The remaining citations either relied solely on clinical diagnoses in registry data (85 \[48%\]), or information was not stated (ten \[6%\]; [table](#tbl1){ref-type="table"}).

We included 44 separate estimates of the incidence of all psychotic disorders derived from 27 citations, including estimates from multicentre studies ([figure 2](#fig2){ref-type="fig"}). Incidence varied around 15 times, from 6·3 per 100 000 person-years (95% CI 4·5--8·8) in Santiago (Spain)[@bib55] to 90·0 (88·3--91·8) in the USA.[@bib54] The overall pooled incidence of all psychotic disorders was 26·6 per 100 000 person-years (22·0--31·7).Figure 2Incidence of all psychotic disordersReferences from 61 onwards are found in the [appendix (pp 35--43)](#sec1){ref-type="sec"}. IR=incidence rates. Note: weights are from random effects analysis.

Incidence of non-affective disorders was available from 47 incidences derived from 28 citations ([figure 3](#fig3){ref-type="fig"}). Incidence varied almost 30 times, from 5·2 per 100 000 years (95% CI 3·7--7·4) in Santiago[@bib55] to 148·4 (142·7--154·4) in Finland.[@bib53] The overall pooled incidence was 18·7 per 100 000 person-years (14·8--23·6), but this incidence was lower in first-contact studies at 17·4 (14·6--20·8) compared with population register studies (pooled incidence rate 90·9 \[34·5--237·5\]; [figure 3](#fig3){ref-type="fig"}). The incidence of schizophrenia was available from 36 incidences from 26 citations and varied from 2·7 per 100 000 person-years (1·4--5·3) in Cavan-Monaghan (Ireland)[@bib43] to 75·9 (74·4--77·5) in South Korea.[@bib52] Pooled incidence was lower in first contact studies (13·1 per 100 000 person-years \[9·0--15·0\]) than in population registers (32·8 \[23·2--46·5\]; [figure 4](#fig4){ref-type="fig"}).Figure 3Incidence of non-affective disordersReferences from 61 onwards are found in the [appendix (pp 35--43)](#sec1){ref-type="sec"}. IR=incidence rates. Note: weights are from random effects analysis.Figure 4Incidence of schizophreniaReferences from 61 onwards are found in the [appendix (pp 35--43)](#sec1){ref-type="sec"}. IR=incidence rates. Note: weights are from random effects analysis.

We pooled 34 estimates of the incidence of affective psychotic disorders from 16 citations. Incidence varied from 0·9 per 100 000 person-years (95% CI 0·4--2·2) in Santiago[@bib55] to 17·0 (10·8--26·6) in Lundby (Sweden).[@bib46] The overall pooled rate was 4·6 per 100 000 person-years (3·1--6·8; [figure 5](#fig5){ref-type="fig"}). 24 estimates of the incidence of bipolar disorder were included in a meta-analysis, derived from 15 citations. Incidence varied from 1·4 per 100 000 person-years (1·0--2·0) in Wales[@bib45] to 28·5 (28·0--29·1) in Sweden,[@bib49] and was higher in population registers (15·1 \[10·2--22·3\]) than first contact studies (3·6 \[2·0--6·5\]; [figure 6](#fig6){ref-type="fig"}). Insufficient citations were available to pool rates for other outcomes.Figure 5Incidence of affective disordersReferences from 61 onwards are found in the [appendix (pp 35--43)](#sec1){ref-type="sec"}. IR=incidence rates. Note: weights are from random effects analysis.Figure 6Incidence of bipolar disorderReferences from 61 onwards are found in the [appendix (pp 35--43)](#sec1){ref-type="sec"}. IR=incidence rates. Note: weights are from random effects analysis.

Pooled estimates of the incidence of all psychotic disorders were similar across high-income and LMICs ([appendix pp 11--16](#sec1){ref-type="sec"}), though heterogeneity was substantial in both sets of data; formal comparisons were hampered by insufficient studies in LMICs.

For all psychotic disorders, 26 estimates of IRRs in men compared with women were available from 10 citations, with a pooled IRR of 1·44 (95% CI 1·27--1·62). A similar pattern was observed for non-affective psychoses (1·60 \[1·44--1·77\]; derived from 27 estimates using 11 citations) and schizophrenia (1·70 \[1·46--1·97\]; derived from 11 estimates using 11 citations). No excess risk in men was found for affective disorders (IRR 0·87 \[0·75--1·00\]; p=0·07; derived from 20 estimates using six citations) or for psychotic bipolar disorder (0·90 \[0·73--1·11\]; derived from five estimates; [appendix p 17](#sec1){ref-type="sec"}). Insufficient citations were available to pool IRRs for other outcomes.

Migrants and their descendants were at excess risk of all psychotic disorders, non-affective disorders, and schizophrenia (insufficient citations were available to synthesise results for other diagnostic outcomes). When pooling all migrant groups to a binary majority or minority division, 22 estimates from seven citations were available to pool IRRs for all psychotic disorders (pooled IRR 1·75 \[95% CI 1·53--2·00\]). The pooled IRR for non-affective disorders was 1·71 (1·40--2·09), derived using 28 estimates from thirteen citations. The pooled IRR for schizophrenia was 1·41 (1·15--1·75), derived using six estimates ([appendix p 18](#sec1){ref-type="sec"}). Risk was not equitably distributed across ethnic minority groups ([appendix pp 19--21](#sec1){ref-type="sec"}).

We did not pool estimates by age group because of the large variety of age groups used. Nonetheless, we observed an overall pattern of higher incidence in younger age groups ([appendix pp 22--24](#sec1){ref-type="sec"}). For example, in the multinational EU-GEI study[@bib55] incidence of all first episode psychosis ranged from 44·2 per 100 000 person-years (95% CI 42·2--46·2) in people aged 18--24 years to 5·5 (3·2--7·7) in people aged 60--64 years.[@bib55]

We found some evidence that study design was associated with variation in incidence. Population registers had higher incidences of non-affective disorders (IRR 9·64 \[2·72--31·82\]), schizophrenia (2·54 \[1·24--5·21\]), and bipolar disorder (4·53 \[2·41--8·51\]) than first contact studies. Incidence of schizophrenia was also elevated in cohort studies (3·10 \[1·12--8·53\]) and case registers (3·12 \[1·33--7·29\]). Cohort studies (0·43 \[0·20--0·93\]) and population registers (0·42 \[0·22--0·83\]) recorded lower IRRs by minority status for non-affective disorders than first contact designs, but we found no differences by study design in IRRs for any other exposure or outcome association. We found little evidence that study quality and time period were associated with changes in incidence or IRR ([appendix pp 25--28](#sec1){ref-type="sec"}).

Heterogeneity was high across study outcomes (*I*^2^ ≥98·5%; [Figure 2](#fig2){ref-type="fig"}, [Figure 3](#fig3){ref-type="fig"}, [Figure 4](#fig4){ref-type="fig"}, [Figure 5](#fig5){ref-type="fig"}, [Figure 6](#fig6){ref-type="fig"}). Small study effects, as evidenced by Egger\'s test, were shown in the overall meta-analyses of incidences of all psychotic disorders (β −7·53 \[SE 3·14\]; p=0·021), non-affective disorders (--14·55 \[2·46\]; p\<0·001), schizophrenia (--11·78 \[5·52\]; p=0·041), affective disorders (7·72 \[1·60\]; p\<0·001), and bipolar disorder (--14·97 \[2·78\]; p\<0·001). They were also found in analyses by sex for all psychotic disorders (2·16 \[0·44\]; p\<0·001) and affective disorders (0·90 \[0·24\]; p=0·001), but not for other diagnostic outcomes or for analyses by ethnic group ([appendix pp 29--32](#sec1){ref-type="sec"}). Post-hoc sensitivity analyses supported some remaining small study effects within first contact designs ([appendix p 32](#sec1){ref-type="sec"}).

Discussion {#cesec70}
==========

Our systematic review identified 177 citations containing data on the incidence of psychotic disorders published since 2002. This yield is considerably higher than reported in another systematic review[@bib19] and was marked by substantial heterogeneity in incidence across all major psychotic disorders. Although we found no evidence that incidences varied with study quality or time period, we did observe strong evidence of higher incidence rates reported in register-based or cohort-based study designs than in first-contact studies. Given that register-based or cohort-based studies are often done with whole population samples (ie, the USA,[@bib51], [@bib54] Sweden,[@bib49] Denmark,[@bib50] Taiwan[@bib48]), this difference was consistent with our evidence of small study effects, whereby smaller studies tended to estimate lower incidence rates. Together with the high levels of statistical heterogeneity observed in our meta-analyses, our results suggest that methodological variation might partially obscure true heterogeneity in the incidence of psychotic disorders. Nonetheless, as previously established, we found strong evidence of higher incidences of all first episode psychosis and non-affective psychotic disorders in men and ethnic minority groups, with less evidence of such differences for affective psychotic disorders.

The strength of our study is that our search strategy was inclusive and based on a previously used strategy with good reliability.[@bib18] We searched multiple databases without restriction by place or language of publication. Although individual studies might have been missed, given the size of our yield we consider it unlikely that these missing data would have substantially altered our main conclusions.

One limitation of our Article was that some citations provided incidence estimates from multiple catchment areas (notably Jongsma and colleagues, 2018),[@bib55] which we included as separate estimates in meta-analyses. We acknowledge this inclusion might have conservatively biased SEs around effect sizes. Nonetheless, it would not have affected our observation of substantial interestimate heterogeneity in incidence, which was the primary focus of our Article. Future studies should consider adopting individual-participant data approaches, which account for clustering by design.[@bib56] We used a previously published, clinician-informed algorithm to group estimates into major psychotic disorder categories.[@bib18] However, for non-affective disorders particularly, the use of this algorithm led to the categorisation of studies that used several overlapping diagnostic outcomes ([appendix pp 33--34](#sec1){ref-type="sec"}), which might have contributed to heterogeneity. Although our quality assessment tool was based on epidemiological good practice, we acknowledge it might have been skewed towards first-contact studies given it is not feasible to assess some criteria (ie, blinding) in register-based designs. Despite this, our quality assessment aided in assessing the gaps in the published literature.

The most recent systematic review and meta-analysis of all psychotic disorders[@bib19] identified substantially fewer citations (N=33) than our Article and provided no assessment or investigation of heterogeneity, despite similar inclusion criteria and time frames. The estimates of our more comprehensive review are aligned: we found a pooled estimate of non-affective disorders of 18·7 per 100 000 person-years (95% CI 14·8--23·7) and of affective disorders of 4·8 (3·3--6·9) compared with their estimates of 22·5 (16·5--28·5) for non-affective and 7·1 (1·4--12·2) for affective disorders.[@bib19] Our findings on the excess of psychoses in men were nuanced: the overall excess found in both reviews appears to be primarily driven by an excess in non-affective disorders in line with other meta-analytic evidence.[@bib27], [@bib28]

The median incidence of schizophrenia in our Article (21·7 per 100 000 person-years \[IQR 5·6--52·0\]) was higher than in the last major systematic review[@bib17] on this topic by McGrath and colleagues (15·2 \[7·7--43·0\]), with greater variation around these estimates. The only systematic review[@bib57] pertaining to mood disorders solely synthesised incidence of major depressive disorder and as such is not directly comparable to the present Article. The excess risk of (non-affective) psychotic disorders in migrants and their descendants is long-established,[@bib58] well-reported,[@bib20], [@bib29] and covered elaborately in one publication.[@bib30]

The present Article presents a varied epidemiological landscape, which partly appears to reflect methodological differences in study design. We found substantial heterogeneity both within and between study designs, with incidences of non-affective disorders, schizophrenia, and bipolar disorder higher in registry-based studies than in first contact studies. Different study designs were more common for different outcomes; for instance, a large proportion of schizophrenia studies were population registers, potentially contributing to this pooled estimate being higher than the pooled estimate of non-affective disorders (a broader category). Although individual studies[@bib36], [@bib37] have done direct comparisons between different study designs, to our knowledge this study is the first systematic review to have investigated such differences. From a public mental health perspective, our results highlight the importance of parsing out potentially causally-relevant signals in geographical variance in incidence from noise generated through varying study designs used in different settings; individual studies[@bib16], [@bib55], [@bib59] that have done so suggest substantive variation in the global burden of psychotic disorders remains.

Nevertheless, more research is required to understand heterogeneity in incidence produced by different study designs. One possible explanation is that register-based studies primarily (though not exclusively) originate from Scandinavian countries, and higher incidences might indicate an association between latitude and psychotic disorders (which is well-reported, but poorly understood).[@bib31] Alternatively, although registry-based studies might ascertain new cases of psychotic disorder across an entire (usually secondary and tertiary) health-care system, not limited to contact with mental health providers, they also rely heavily on diagnoses made in clinical practice. Although such diagnoses are reliable,[@bib60] first-contact studies are often able to include standardised diagnostic assessments, which might reduce the number of false positives, leading to lower reported incidence. Small study effects are not necessarily due to publication bias[@bib41] and in our Article are consistent with the possibility of lower incidence rates reported in first contact designs; registry-based or insurance database-based studies tended to include a larger number of cases ([table](#tbl1){ref-type="table"}). However, sensitivity analyses ([appendix p 32](#sec1){ref-type="sec"}) suggest some within-type small study effects remained, which might reflect real variance between for instance urban (where a large number of cases accrue) and rural areas. In this Article, we were unable to assess effects of urbanicity, latitude, or other socioeconomic variables due to the preponderance of country-wide estimates for which no meaningful values could be assigned.

The geographical spread of studies in this Article remained mostly limited to Europe, Northern America, or Australia. One public health implication of our findings is the continued dearth of evidence outside of these settings, which might have profound consequences; for example, a cross-sectional study[@bib16] suggested the well established link between urbanicity and psychosis might not apply in LMICs. To fully understand and provide effective public mental health responses to the global burden of psychotic disorders, we will require methodologically-rigorous and culturally-appropriate epidemiological studies to delineate the incidence of psychotic disorders in a broader range of settings than has thus far been considered.

Finally, our findings also suggest that developing international guidelines for investigation of the incidence of psychotic disorders in different settings could help minimise methodological heterogeneity in the reporting of psychosis incidence across the globe.
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